External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ACR 2024
Roche and Genentech at

ACR 2024

November 14 - November 19
Washington DC, USA
acr.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Nov 17 / Roche and Genentech
Characteristics and treatment patterns of patients with lupus nephritis: a retrospective claims database study in the USA
This retrospective, observational cohort study assessed first-line treatment patterns among newly diagnosed patients with lupus nephritis overall and by time period (before or on/after Jan 1, 2021), by prior use of any immunosuppressants and by race and ethnicity.
Nephrology Lupus nephritis ACR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 16 / Roche and Genentech
Evaluating the concordance between SRI-4 and BICLA in the EXPLORER and ATHOS trials in active systemic lupus erythematosus
This post hoc analysis of 2 systemic lupus erythematosus randomized controlled trials (EXPLORER [NCT00137969] and ATHOS [NCT02908100]) examined concordance in British Isles Lupus Assessment Group (BILAG)–based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI-4) outcome measures among participants receiving placebo and standard of care, and explored reasons for BICLA and SRI-4 discordance.
Immunology Systemic Lupus Erythematosus ACR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 16 / Roche and Genentech
Obinutuzumab Benefits Patients With Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: a Post Hoc Analysis of a Phase II Trial
This post hoc analysis assessed the achievement of complete renal response (CRR) in participants with lupus nephritis from the Phase 2 NOBILITY trial (NCT02550652) using primary endpoint definitions from the ongoing Phase 3 REGENCY (NCT04221477) and completed BLISS-LN trials. In addition, this analysis evaluated the effect of proteinuria at baseline on achieving the REGENCY CRR.
Nephrology Lupus nephritis ACR-2024
03:30 PM
Duration 2hrs Washington DC, USA
Understanding the Patient Burden of Lupus: Insights From a Multi-Faceted Ethnography Research
Andersen J, Meyer I, Camadoo N, Machado T, Saraf S, Akrout M
Nephrology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs Washington DC, USA
Evaluating the concordance between SRI-4 and BICLA in the EXPLORER and ATHOS trials in active systemic lupus erythematosus
Askanase A, Vital EM, Meier O, Turchetta A, Mao H(A), Maller J, Terres JAR, Dall'Era M
Immunology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs Washington DC, USA
Obinutuzumab Benefits Patients With Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: a Post Hoc Analysis of a Phase II Trial
Furie RA, Terres JAR, Martins E, Hassan I, Schindler T, Garg J, Pendergraft W, Malvar A, Rovin B
Nephrology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 2hrs Washington DC, USA
Characteristics and treatment patterns of patients with lupus nephritis: a retrospective claims database study in the USA
Patel A, Xia Z, Lindsay L, Ng C, Pendergraft W, Dall'Era M
Nephrology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.